roi-nj.com /4 weeks ago

Bristol Myers Squibb reports interim MS data from CAR T study

Bristol Myers Squibb announced Oct. 23 interim safety and efficacy results from a Phase 1 study evaluating an investigational CAR T cell therapy in patients with highly active rela...

Read source
qchron.com /4 weeks ago

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Genera...

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China

Read source
qchron.com /1 month ago

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Nega...

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II...

Read source
qchron.com /4 weeks ago

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Ca...

GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars,...

Read source
qchron.com /2 weeks ago

Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibod...

Read source
bioengineer.org /1 month ago

New Antibody Targets BAMBI to Rewire Immune Cells in Psoriatic Arthritis

Spanish researchers have developed a humanized monoclonal antibody, hB101.37, that inhibits the BAMBI pseudoreceptor and rebalances T cell immunity, showing therapeutic efficacy an...

Read source
biopharmadive.com /3 weeks ago

Another autoimmune CAR-T death; Treasury zeroes in on China deals

A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.

Read source
qchron.com /3 weeks ago

Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders wit...

HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company fo...

Read source
qchron.com /1 week ago

Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ded...

Read source
pharmexec.com /3 weeks ago

<![CDATA[Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial ]]>

Read source
newswire.com /2 weeks ago

DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee

Corexa Pharmacy to dispense compounded BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax in accordance with HHS' recently updated Enforcement Discretion PolicyBulk drug substance ac...

Read source
investing.com /2 weeks ago

Bristol Myers Squibb presents 56-week Camzyos trial data

Read source
qchron.com /1 week ago

PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FD...

PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor respo...

Read source
qchron.com /3 weeks ago

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatme...

- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.

Read source
qchron.com /1 month ago

First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-...

Read source
pharmexec.com /5 days ago

<![CDATA[FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated wit...

Read source
qchron.com /4 weeks ago

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO...

SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinic...

Read source
qchron.com /2 weeks ago

Verismo Therapeutics to Present First-in-Human SynKIRâ„¢-310 KIR-CAR Clinical Data Showing Robust Antitumor Activity and...

Interim clinical data of SynKIRâ„¢-310, a CD19-targeted KIR-CAR T therapy, showed no CRS, ICANS, or DLT in the first two dose levels, coupled with robust antitumor activity in pati...

Read source
pharmexec.com /2 weeks ago

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro]]>

Read source
qchron.com /3 weeks ago

Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders wit...

Read source
newswire.com /6 days ago

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Re...

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy ad...

Read source
healio.com /6 days ago

First-in-class therapy may improve clinical remission in ulcerative colitis

A receptor-interacting protein kinase 2 scaffolding inhibitor significantly improved clinical remission in moderately to severely active ulcerative colitis, according to results pr...

Read source
healio.com /6 days ago

First-in-class therapy may improve clinical remission in ulcerative colitis

A receptor-interacting protein kinase 2 scaffolding inhibitor significantly improved clinical remission in moderately to severely active ulcerative colitis, according to results pr...

Read source
newswire.com /1 month ago

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.